Cerus (STU:CU2) Moat Score: 6/10 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CU2 Cerus Corp STU:CU2
78 GF Score
Price €2.34
GF Value €1.97
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cerus Moat Score?

Cerus STU:CU2 +0.86% 78 Moat Score is 6 as of Aug. 27, 2026. GuruFocus rates STU:CU2 with a GF Score™ of 78/100 and a GF Value™ of €1.97 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 835 Medical Devices & Instruments companies, Cerus ranks better than 95.69% on this metric.

Cerus has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Cerus has Narrow Moat: CERS has strong intellectual property and regulatory barriers in the blood safety sector. Its innovation and R&D capabilities support a strong narrow moat, but it lacks the breadth of advantages needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cerus might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Cerus  (STU:CU2) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cerus Moat Score Related Terms

STU:CU2 vs CTKB, TCMD, CBLL: Moat Score Comparison

For the Medical Devices subindustry, Cerus's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerus Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Moat Score distribution charts can be found below:

* The bar in red indicates where Cerus's Moat Score falls into.


STU:CU2
78GF Score
Cerus Corp STU:CU2
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Cerus (STU:CU2) has a Moat Score of 6 as of Aug. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cerus ranks #36 out of 835 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is Cerus' Moat Score too high?
Cerus' current Moat Score is 6. Based on the distribution chart, Cerus ranks #36 out of 835 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Cerus has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cerus' Moat Score compare to CTKB and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cerus ranks #36 out of 835 companies for Moat Score. This places Cerus in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cerus's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cerus stock overvalued right now?
Based on GuruFocus' analysis, Cerus (STU:CU2) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.97, compared to a current price of €2.34 — trading 18.8% above its estimated fair value. The current Moat Score is 6. Cerus' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cerus (STU:CU2), the current Moat Score is 6 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cerus (STU:CU2) Overvalued in 2026?

Based on GuruFocus' analysis, Cerus stock appears to be overvalued. The current stock price of €2.34 is trading 18.8% above its estimated GF Value™ of €1.97. GuruFocus considers Cerus to be Modestly Overvalued.

Key valuation signals for STU:CU2:

  • Moat Score: 6
  • GF Value™: €1.97 vs. price of €2.34 (18.8% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the STU:CU2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cerus Business Description

Other Exchanges CERS:USA
Address 1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score

Get the complete analysis for STU:CU2

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.34
Price
€1.97
GF Value